The full research publication is available at: (25)00035-2/fulltext Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging ...

fueled by better understanding about the biological and cytogenetic underpinnings of multiple myeloma and its precursor stages, monoclonal gammopathy of undetermined significance (MGUS ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory ...

While there is no cure for multiple myeloma, increased awareness about the symptoms can be the key to timely diagnosis and ...

Presented in part at the American Society of Hematology 64th Annual Meeting and Exposition, New Orleans, LO, December 10-13, 2022. Supported in part by a Jacquelin Forbes-Nixon Fellowship (to M.F.K.) ...

The following is a summary of “BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma,” published in ...